Using REMS to Ram Drugs through the FDA Faster

By Cole Werble, IN VIVO 11/1/2007

• Feature Articles
• Word Count: 930
• Art # 2007800179

Executive Summary

IN VIVO -- FDA's use of Risk Evaluation & Mitigation Strategies will require NDA and BLA sponsors to provide more rigorous definitions of patient populations. Former FDA Commissioner Kessler thinks that may break the logjam on approvals. (Sidebar to the article, "Evolution in Strategies for Getting FDA Approvals." ) This is a sidebar to the article, "The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Approvals."

For $85, purchase this 930-word article as a PDF, and receive immediate delivery via email. View a complete sample article.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.

100% Satisfaction Guarantee